Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
$4.13
-$0.02(-0.90%)
At close: 4:00 PM EST
$4.13
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.11 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)99.38K
Market Cap
$616.04M
Enterprise Value$270.96M
Total Cash (Recent Filing)$96.56M
Total Debt (Recent Filing)$54.33M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Apr 01, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding145,951,280
10 Day Avg. Volume175,727
30 Day Avg. Volume99,378
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.01
Price to Sales (P/S)11.68
P/FCF Ratio-1.25
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue29.46
Enterprise Value/Gross Profit29.46
Enterprise Value/Ebitda-1.63
Forecast
1Y Price Target
$17.86Price Target Upside332.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessLanifibranor remains the only agent to hit both endpoints in a 24-week trial, showing a significant fibrosis improvement compared to placebo.
MASH Treatment InnovationLanifibranor is uniquely positioned as a fibrosis directed, insulin-sensitizing oral therapy in a landscape where most competitors are injectable and weight centric.
Strategic LeadershipThe leadership transition reflects a strategic decision by the Board with a particular focus on preparing for the potential commercialization of lanifibranor.
Bears Say
Fibrosis ChallengeFibrosis has been the most difficult feature of MASH to address, but remains the most clinically relevant given its strong association with outcomes.
Market DisparityIVA shares dropped significantly due to a disparity between the price of the ADR and shares traded on the Euronext Paris exchange.
Safety ConcernsPioglitazone faces a number of tolerability/safety concerns that limit its use.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $2.11 and its highest was $7.98 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $616.04M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Apr 01, 2026 which is in 131 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 29, 2025. The company reported -$1.616 earnings per share for the quarter, missing the consensus estimate of -$0.63 by -$0.986.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.49.
How many shares outstanding does Inventiva have?
Inventiva has 145,951,280 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.616 in its last earnings report, missing expectations of -$0.63. Following the earnings report the stock price went down -2.975%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.86 (332.45% Upside)
$17.86 (332.45% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
399.59%
Trailing 12-Months
Company Description
Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Stock 12 Month Forecast
Average Price Target
$17.86
▲(332.45% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
3.31% Other Institutional Investors
96.69% Public Companies and Individual Investors
Options Prices
Currently, No data available
---